Propranolol vs PT-141
FDA Approved vs FDA Approved
monitor Mechanism-based · 60% Both Propranolol and PT-141 can raise blood pressure. Monitor BP regularly and consider adding cardiovascular support (cardarine, telmisartan, or similar).
Molecular Data
Propranolol PT-141
Weight 259.34 Da —
Half-life ~4-5 hours ~2.7 hours
Type Aryloxypropanolamine derivative (C16H21NO2) Melanocortin receptor agonist
Key Benefits
Propranolol
01 Rapid reduction of elevated heart rate within 30-60 minutes of oral dosing
02 Effective against tachycardia from both trenbolone and clenbuterol through non-selective beta blockade
03 Well-established anxiolytic effect for performance anxiety without cognitive impairment or sedation
04 Short half-life allows flexible as-needed dosing without prolonged hemodynamic effects
05 Extensive clinical safety data spanning over 50 years of use
06 Inexpensive and widely available as a generic medication
07 Does not cause dependence or withdrawal symptoms typical of benzodiazepines
08 Effective for controlling physical anxiety symptoms (tremor, palpitations, sweating)
PT-141
01 FDA-approved pharmaceutical route
02 Predictable absorption profile
03 Effective for both male and female sexual dysfunction
04 Works within 45 minutes
05 Effective in PDE5 inhibitor-resistant cases
06 Central mechanism (not dependent on blood flow)
Dosing Protocols
Propranolol
10-80 mg/day / 1-3 times daily (or as needed)
PT-141
Women: 1.75mg (FDA-approved); Men: 1-2mg; Start 0.5mg test dose for tolerance / As needed before sexual activity; max 1 dose per 24 hours
Female HSDD (FDA-approved) 1.75mg As needed, max 1 dose/24hr
Male Erectile Dysfunction 1-2mg As needed, 45-60min before activity
Female Arousal Disorder 0.75-1.25mg As needed, max 1 dose/24hr
Low Starting Dose 0.5mg Test dose for tolerance assessment
Side Effects
Propranolol
Fatigue and reduced exercise tolerance, particularly during the first week of use
Cold extremities (hands and feet) due to beta-2 blockade of peripheral vasodilation
Bradycardia (heart rate below 60 bpm), usually dose-dependent and asymptomatic
Dizziness or lightheadedness, especially when standing quickly
Gastrointestinal discomfort (nausea, diarrhea, constipation)
PT-141
Nausea (40%)
Flushing (20%)
Headache (11%)
Injection site reactions
Contraindications
Asthma or severe reactive airway disease (non-selective beta blockade can trigger life-threatening bronchospasm)
Decompensated heart failure or cardiogenic shock
Sinus bradycardia (resting HR below 50 bpm) or second/third-degree heart block
Severe peripheral arterial disease or Raynaud's syndrome
Pheochromocytoma without prior alpha blockade (risk of hypertensive crisis from unopposed alpha stimulation)
Uncontrolled hypertension
Cardiovascular disease
Use of nitrate medications
Pregnancy or breastfeeding
Research Evidence
Propranolol PT-141
Status FDA Approved FDA Approved
References 5 studies 4 studies
Latest 2023 2022
FDA Approved Yes Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.